T Cell Transfection by mRNA Lipid Nanoparticles using PreciGenome NanoGenerator System

Since the first FDA approval of chimeric antigen receptor (CAR) T-cell therapy at 2017, T cells engineering is continuously the hottest research field in immunotherapy and cell therapy. Current CAR T cell engineering methods use viral transductions, which induce permanent CAR expression and have potential safety concerns. To overcome this concerns, researchers are highly interested in non-viral gene delivery methods. 

Recently, CAR mRNA lipid nanoparticles (LNPs) in T-cell engineering have been widely studied. The transient transduction feature of mRNA LNP make it a safer profile than viral vectors. The size, homogeneousness and mRNA encapsulation efficiency are the key factors for an efficiency T-cell transfection. Using PreciGenome’s NanoGenerator system, customer can produce mRNA LNPs with well controlled size, high homogeneousness and excellent encapsulation efficiency. 

The following data shows the size and PDI of GFP mRNA lipid nanoparticles synthesized by NanoGenerator Flex system. The transfection efficiency to K562 and HepG2 cell lines and human primary T cells are presented as well.